Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
ENHANCED COAGULATION AND FIBRINOLYSIS DURING TREATMENT WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN IN PATIENTS UNDERGOING CHRONIC-HEMODIALYSIS
Autore:
TOMURA S; NAKAMURA Y; TACHIBANA K; DEGUCHI F; ANDO R; CHIDA Y; MARUMO F;
Indirizzi:
NAKANO GEN HOSP,DEPT INTERNAL MED,NAKANO KU,4-59-16 CHUO TOKYO 164 JAPAN TOKYO MED & DENT UNIV TOKYO 113 JAPAN
Titolo Testata:
Blood purification
fascicolo: 6, volume: 11, anno: 1993,
pagine: 370 - 377
SICI:
0253-5068(1993)11:6<370:ECAFDT>2.0.ZU;2-F
Fonte:
ISI
Lingua:
ENG
Keywords:
COAGULATION; FIBRINOLYSIS; RECOMBINANT HUMAN ERYTHROPOIETIN; REGULAR HEMODIALYSIS TREATMENT;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
NO
Recensione:
Indirizzi per estratti:
Citazione:
S. Tomura et al., "ENHANCED COAGULATION AND FIBRINOLYSIS DURING TREATMENT WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN IN PATIENTS UNDERGOING CHRONIC-HEMODIALYSIS", Blood purification, 11(6), 1993, pp. 370-377

Abstract

Twenty-two patients on regular hemodialysis treatment suffering from renal anemia were treated with intravenous recombinant human erythropoietin (rhEPO) for more than 8 weeks. Before and 4 and 8 weeks after the start of rhEPO administration, we measured prothrombin time, activated partial thromboplastin time, fibrinogen (FBG), antithrombin III activity (ATIII), plasminogen activity (PLG), alpha(2)-plasmin inhibitor activity (alpha(2)PI), alpha(2)-plasmin inhibitor-plasmin complex (alpha(2)PIC), and cross-linked fibrin degradation products (XL-FDP) in citrated plasma to determine whether rhEPO treatment enhances coagulation and fibrinolytic activity. The pretreatment values of FBG, alpha(2)PIC, and XL-FDP were significantly higher than the normal control values. The pretreatment values of ATIII, PLG, and alpha(2)PI were significantly lower than the normal control values. Platelet count and FBG were significantly increased 4 and 8 weeks after treatment with rhEPO. The prothrombin time was significantly shortened 8 weeks after rhEPO treatment, but the activated partial thromboplastin time did not change. PLG was significantly decreased 4 and 8 weeks after rhEPO treatment, and ATIII and alpha(2)PI were significantly decreased 8 weeks after rhEPO treatment. alpha(2)PIC was significantly increased 8 weeks after rhEPO treatment, and XL-FDP was significantly increased 4 and 8 weeks after rhEPO treatment. These data suggest that in patients on regular hemodialysis treatment coagulation and fibrinolysis are already enhancedbefore the start of rhEPO treatment and that rhEPO administration further enhances these disorders.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/04/20 alle ore 09:19:12